生化机理 |
TAK-901 is a small-molecule inhibitor of the serine-threonine kinase Aurora B with potential antineoplastic activity. Aurora B is a positive regulator of mitosis that functions in the attachment of the mitotic spindle to the centromere. This serine/threonine kinase may be amplified and overexpressed by a variety of cancer cell types. After binding of TAK-901 to Aurora B, it inhibits the activity of Aurora B, which may result in a reduction in the proliferation of tumor cells that overexpress Aurora B. TAK-901 is originally developed by Millennium Pharmaceuticals, Inc.. And TAK-901 is been performed phase I clinical trials for the treatment of advanced solid tumors and lymphoma. |